SCHEMBL1337871

SCHEMBL1337871

Nc1ccc(-c2cccc(OC3CC3)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.50
SLC6A3 Q01959 2/20 0.50
SLC6A4 P31645 1/20 0.50
TAAR1 Q96RJ0 2/20 0.47
CYP3A4 P08684 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
HSD17B10 Q99714 1/20 0.43
MAOB P27338 2/20 0.41
EPHX2 P34913 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
MITF O75030 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NLRP1 Q9C000 1/20 0.41
NOD2 Q9HC29 1/20 0.41
FFAR1 O14842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337890 0.82 DHODH (0.46) SLC6A2SLC6A3SLC6A4TAAR1FFAR1
SCHEMBL17027815 0.81 MAP4K4 (0.59) SLC6A2SLC6A3SLC6A4DHODHIGF1R
SCHEMBL22926441 0.80 DRD1 (0.57) SLC6A2SLC6A3SLC6A4EPHX2ALDH1A1
SCHEMBL1337675 0.80 DHODH (0.49) SLC6A2SLC6A3SLC6A4EPHX2FFAR4
SCHEMBL29622788 0.79 ALDH1A1 (0.65) TAAR1CYP3A4TDP1HSD17B10MAOB
SCHEMBL30361750 0.79 CYP3A4 (0.54) SLC6A2SLC6A3SLC6A4CYP3A4MAOB
SCHEMBL14155651 0.79 CYP3A4 (0.54) SLC6A2SLC6A3SLC6A4CYP3A4MAOB
SCHEMBL2595252 0.79 SLC6A2 (0.55) SLC6A2SLC6A3SLC6A4TAAR1SMN1; SMN2
SCHEMBL7228791 0.78 SLC6A4 (0.52) SLC6A2SLC6A3SLC6A4EPHX2
SCHEMBL16242368 0.77 RXRA (0.49) SLC6A2SLC6A3SLC6A4CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR SLC6A2 4033/4885SLC6A3 3798/4885SLC6A4 3641/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR SLC6A2 4033/4885SLC6A3 3798/4885SLC6A4 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.